未登录Real-World Evidence from a Nationwide Prospective Study of the Efficacy/Safety of Systemic Therapy for Unresectable Hepatocellular Carcinoma: First 1,000 Patients of the PRISM Study全国性前瞻性研究中的真实世界证据：不可切除肝细胞癌系统性治疗的有效性/安全性分析——PRISM研究的前1000例患者
Ikeda, Masafumi; Itoh, Shinji; Onozuka, Daisuke; Ogasawara, Sadahisa; Kawaoka, Tomokazu; Niizeki, Takashi; Yamashita, Taro; Tanaka, Yasuhito; Yamada, Tomoharu; Numata, Kazushi; Tateishi, Ryosuke; Yamashita, Tatsuya; Okusaka, Takuji; Furuse, Junji; Kudo, Masatoshi .png)
分享.png)
收藏分享 收藏 分享 收藏 The SELENOP Polymorphism rs7579 Predicts Hepatic Steatosis in Females With Insulin Resistance in the General PopulationSELENOP多态性rs7579可预测普通人群中胰岛素抵抗女性的肝脂肪变性。Yamamoto, Reina; Takeshita, Yumie; Takayama, Hiroaki; Tsujiguchi, Hiromasa; Kannon, Takayuki; Sato, Takehiro; Hosomichi, Kazuyoshi; Suzuki, Keita; Tanaka, Takeo; Goto, Hisanori; Nakano, Yujiro; Yamashita, Tatsuya; Kaneko, Shuichi; Honda, Masao; Saito, Yoshiro; Tajima, Atsushi; Nakamura, Hiroyuki; Takamura, Toshinari 分享 收藏 Nivolumab plus Ipilimumab versus Lenvatinib or Sorafenib as First-Line Treatment for Unresectable Hepatocellular Carcinoma: CheckMate 9DW Japanese Subgroup Analysis纳武利尤单抗联合伊匹木单抗对比仑伐替尼或索拉非尼作为不可切除肝细胞癌的一线治疗：CheckMate 9DW日本亚组分析Kudo, Masatoshi; Hiraoka, Atsushi; Numata, Kazushi; Yamashita, Tatsuya; Kurosaki, Masayuki; Namisaki, Tadashi; Hige, Shuhei; Itoh, Yoshito; Mochida, Satoshi; Hosaka, Tetsuya; Akuta, Norio; Kawaoka, Tomokazu; Genda, Takuya; Kobayashi, Satoshi; Uchida-Kobayashi, Sawako; Lu, Yuting; Ogata, Tatsuya; Jimenez Exposito, Maria Jesus; Ikeda, Masafumi 分享 收藏 Protocol of the IMPACT study: randomized, multicenter, phase 3 study evaluating the efficacy of immunotherapy (Atezolizumab) plus anti-VEGF therapy (Bevacizumab) in combination with transcatheter arterial chemoembolization for unresectable hepatocellular carcinomaKodama, Yoshihisa; Ueshima, Kazuomi; Moriguchi, Michihisa; Inaba, Yoshitaka; Yamashita, Tatsuya; Iwamoto, Hideki; Ueno, Makoto; Ogasawara, Sadahisa; Kuzuya, Teiji; Kodama, Takahiro; Sato, Yozo; Tada, Toshifumi; Tsuchiya, Kaoru; Nishiofuku, Hideyuki; Yamakado, Koichiro; Sone, Miyuki; Ikeda, Masafumi; Takehara, Tetsuo; Hamano, Tetsutaro; Kudo, Masatoshi 分享 收藏 Impact of the revised Japanese indication criteria for deceased donor liver transplantation on liver cirrhotic patients of Child-Pugh classification B with hepatocellular carcinomaSeki, Akihiro; Yamashita, Tatsuya; Terashima, Takeshi; Nakanuma, Shinichi; Okazaki, Mitsuyoshi; Kido, Hidenori; Nishitani, Masaki; Miyazawa, Masaki; Takata, Noboru; Hayashi, Tomoyuki; Nakagawa, Hidetoshi; Horii, Rika; Nio, Kouki; Yamada, Shinya; Takatori, Hajime; Shimakami, Tetsuro; Honda, Masao; Yagi, Shintaro; Yamashita, Taro 分享 收藏 Final analysis of the REPLACEMENT study: a phase II study of atezolizumab plus bevacizumab (atezo plus bev) for patients (pts) with Transcatheter arterial chemoembolization (TACE)-unsuitable intermediate-stage hepatocellular carcinoma (HCC) beyond the up-to-seven criteriaREPLACEMENT研究的最终分析：一项关于阿替利珠单抗联合贝伐珠单抗（atezo plus bev）治疗经肝动脉化疗栓塞（TACE）不适宜的超出“七例标准”的中期肝细胞癌（HCC）患者的II期研究Yamashita, T.; Ueshima, K.; Tsuchiya, K.; Kato, N.; Shimose, S.; Numata, K.; Kodama, Y.; Ohkawa, K.; Kuzuya, T.; Ikeda, M.; Kooka, Y.; Aikata, H.; Hiraoka, A.; Moriguchi, M.; Fujiwara, K.; Suda, G.; Mochida, S.; Ogasawara, S.; Yamamoto, K.; Kudo, M. 分享 收藏 Hepatokine leukocyte cell-derived chemotaxin 2 as a biomarker of insulin resistance, liver enzymes, and metabolic dysfunction-associated steatotic liver disease in the general populationSuzuki, Keita; Tsujiguchi, Hiromasa; Hara, Akinori; Takeshita, Yumie; Goto, Hisanori; Nakano, Yujiro; Yamamoto, Reina; Takayama, Hiroaki; Tajima, Atsushi; Yamashita, Tatsuya; Honda, Masao; Nakamura, Hiroyuki; Takamura, Toshinari 分享 收藏 Comprehensive genomic profiling for advanced hepatocellular carcinoma in clinical practiceTerashima, Takeshi; Yamashita, Tatsuya; Arai, Kuniaki; Takata, Noboru; Hayashi, Tomoyuki; Seki, Akihiro; Nakagawa, Hidetoshi; Nio, Kouki; Iida, Noriho; Yamada, Shinya; Shimakami, Tetsuro; Takatori, Hajime; Tsuji, Kunihiro; Sunagozaka, Hajime; Mizukoshi, Eishiro; Honda, Masao; Takeuchi, Shinji; Yamashita, Taro 分享 收藏 分享 收藏 Efficacy and safety of liposomal irinotecan plus S-1 in patients with metastatic pancreatic cancer after failure of first-line gemcitabine-based chemotherapy: Result of a phase I/II study脂质体伊立替康联合S-1在经吉西他滨为基础的一线化疗失败的转移性胰腺癌患者中的疗效与安全性：一项I/II期研究的结果Imaoka, H.; Ikeda, M.; Ozaka, M.; Oshima, K.; Okano, N.; Shimizu, S.; Tsumura, H.; Komatsu, Y.; Yamashita, T.; Kataoka, S.; Nagano, H.; Hisano, T.; Sasaki, M.; Kobayashi, S.; Fukushima, T.; Mitsunaga, S.; Furukawa, T.; Hamauchi, S.; Hedouin-Biville, F.; Ueno, M. 分享 收藏 分享 收藏 Potential utility of l-carnitine for preventing liver tumors derived from metabolic dysfunction-associated steatohepatitisLyu, Junyan; Okada, Hikari; Sunagozaka, Hajime; Kawaguchi, Kazunori; Shimakami, Tetsuro; Nio, Kouki; Murai, Kazuhisa; Shirasaki, Takayoshi; Yoshida, Mika; Arai, Kuniaki; Yamashita, Tatsuya; Tanaka, Takuji; Harada, Kenichi; Takamura, Toshinari; Kaneko, Shuichi; Yamashita, Taro; Honda, Masao 分享 收藏 Serum MYCN as a predictive biomarker of prognosis and therapeutic response in the prevention of hepatocellular carcinoma recurrence血清MYCN作为预测预后和治疗反应的生物标志物在预防肝细胞癌复发中的作用Qin, Xian-Yang; Shirakami, Yohei; Honda, Masao; Yeh, Shiou-Hwei; Numata, Kazushi; Lai, Ya-Yun; Li, Chiao-Ling; Wei, Feifei; Xu, Yali; Imai, Kenji; Takai, Koji; Chuma, Makoto; Komatsu, Nagisa; Furutani, Yutaka; Gailhouste, Luc; Aikata, Hiroshi; Chayama, Kazuaki; Enomoto, Masaru; Tateishi, Ryosuke; Kawaguchi, Kazunori; Yamashita, Tatsuya; Kaneko, Shuichi; Nagaoka, Katsuya; Tanaka, Motohiko; Sasaki, Yutaka; Tanaka, Yasuhito; Baba, Hideo; Miura, Kouichi; Ochi, Sae; Masaki, Takahiro; Kojima, Soichi; Matsuura, Tomokazu; Shimizu, Masahito; Chen, Pei-Jer; Moriwaki, Hisataka; Suzuki, Harukazu 分享 收藏 Impact of Bevacizumab Being Skipped due to Adverse Events of Special Interest for Bevacizumab in Patients With Unresectable Hepatocellular Carcinoma Treated With Atezolizumab Plus Bevacizumab: An Exploratory Analysis of the Phase III IMbrave150 studyKudo, Masatoshi; Tsuchiya, Kaoru; Shao, Yu-Yun; Finn, Richard S.; Galle, Peter R.; Ducreux, Michel; Cheng, Ann-Lii; Yamashita, Tatsuya; Koga, Hironori; Take, Ryosuke; Yamada, Kyoko; Asakawa, Takashi; Nakagawa, Yuki; Ikeda, Masafumi 分享 收藏 IMPACT: Randomized, multicenter, phase III study evaluating the efficacy of immunotherapy (atezolizumab) plus anti-VEGF therapy (bevacizumab) in combination with transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma (HCC)Yamashita, T.; Inaba, Y.; Ikeda, M.; Sone, M.; Yamakado, K.; Nishiofuku, H.; Tsuchiya, K.; Tada, T.; Sato, Y.; Kodama, T.; Kuzuya, T.; Ogasawara, S.; Ueno, M.; Iwamoto, H.; Moriguchi, M.; Ueshima, K.; Kodama, Y.; Takehara, T.; Hamano, T.; Kudo, M. 分享 收藏 Successful second-line treatment with cabozantinib for hepatocellular carcinoma harboring cytoplasmic mesenchymal-epithelial transition factor amplificationYamamoto, Makoto; Terashima, Takeshi; Yamashita, Tatsuya; Seki, Akihiro; Nakagawa, Hidetoshi; Nio, Kouki; Shimakami, Tetsuro; Takatori, Hajime; Arai, Kuniaki; Mizukoshi, Eishiro; Honda, Masao; Takeuchi, Shinji; Yamashita, Taro 分享 收藏 Nab-paclitaxel plus gemcitabine versus modified FOLFIRINOX or S-IROX in metastatic or recurrent pancreatic cancer (JCOG1611, GENERATE): A multicentred, randomized, open-label, three-arm, phase II/III trialOhba, A.; Ozaka, M.; Ogawa, G.; Okusaka, T.; Kobayashi, S.; Yamashita, T.; Ikeda, M.; Yasuda, I.; Sugimori, K.; Sasahira, N.; Ikezawa, K.; Miki, I.; Okano, N.; Mizuno, N.; Furukawa, M.; Shirakawa, H.; Sano, Y.; Katayama, H.; Furuse, J.; Ueno, M. 分享 收藏 Multicenter Phase II trial of lenvatinib plus hepatic intra-arterial infusion chemotherapy with cisplatin for advanced hepatocellular carcinoma: LEOPARDIkeda, Masafumi; Yamashita, Tatsuya; Ogasawara, Sadahisa; Kudo, Masatoshi; Inaba, Yoshitaka; Morimoto, Manabu; Tsuchiya, Kaoru; Shimizu, Satoshi; Kojima, Yasushi; Hiraoka, Atsushi; Nouso, Kazuhiro; Aikata, Hiroshi; Numata, Kazushi; Sato, Tosiya; Okusaka, Takuji; Furuse, Junji 分享 收藏 
.png){kind=icon}
.png){kind=icon}
.png)
ANNALS OF ONCOLOGY.png)
OAAI